New US Preventive Service Task Force recommendations for prostate cancer screening: a needed update, but not enough

Prostate cancer (PC) screening remains a controversial topic, although it has been studied for more than two decades. Since the 1990s, when the use of Prostate-Specific Antigen (PSA) began in clinical practice, the mortality rate from PC has decreased by around 50%. Prostate cancer screening policies, early diagnosis and treatment are pointed out as responsible to 45%-70% of this reduction.() On the other hand, indiscriminate screening can lead to problems because of unnecessary prostate biopsies, and their possible side effects, [...]